Hazan Sabine
Progenabiome, LLC, Ventura, CA, United States.
Front Microbiol. 2022 Jul 11;13:952321. doi: 10.3389/fmicb.2022.952321. eCollection 2022.
Ivermectin is an anti-parasitic agent that has gained attention as a potential COVID-19 therapeutic. It is a compound of the type Avermectin, which is a fermented by-product of . is a member of the same phylum as spp., suggesting it may have a symbiotic relation with . Decreased levels are observed in COVID-19 susceptibility states, including old age, autoimmune disorder, and obesity. We hypothesize that Ivermectin, as a by-product of fermentation, is capable of feeding , thereby possibly preventing against COVID-19 susceptibilities. Moreover, may be capable of boosting natural immunity, offering more direct COVID-19 protection. These data concord with our study, as well as others, that show Ivermectin protects against COVID-19.
伊维菌素是一种抗寄生虫药物，作为一种潜在的新冠治疗药物而受到关注。它是阿维菌素类型的化合物，是……的发酵副产物。……与……属于同一门，这表明它可能与……有共生关系。在包括老年、自身免疫性疾病和肥胖在内的新冠易感性状态中观察到……水平降低。我们假设，作为……发酵的副产物，伊维菌素能够为……提供养分，从而有可能预防新冠易感性。此外，……可能能够增强自然免疫力，提供更直接的新冠防护。这些数据与我们的研究以及其他研究一致，这些研究表明伊维菌素可预防新冠。
